IGF::OT::IGF LOW MOLECULAR WEIGHT TSH HORMONE RECEPTOR AGONIST FOR THYROID CANCER

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$289,639.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
N43CO120057
Agency Tracking Number:
N43CO120057
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
BETHESDA PHARMA, LLC
2400 Research Blvd Suite 310, ROCKVILLE, MD, 20850-6252
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
078275910
Principal Investigator:
RUKHSANA RAHMAN
(301) 983-4006
RUKHSANA627@GMAIL.COM
Business Contact:
RUKHSANA RAHMAN
(301) 983-4006
RUKHSANA627@GMAIL.COM
Research Institution:
Stub




Abstract
Following ablative surgery for thyroid cancer, follow-up management of patients includes monitoring for radioiodine uptake or serum TG levels. Recombinant human thyroid stimulating hormone (rhTSH) is currently used to increase the sensitivity of measurements in patients on thyroid hormone replacement; however, rhTSH is expensive to produce and requires injection for delivery. A small-molecule thyroid stimulating hormone receptor (TSHR) agonist may offer the beneficial effects as rhTSH but at a lower cost and with oral administration. We propose here to evaluate Compound 1 (NCGC reference # 00161870-01) for its potential as a clinically translatable TSHR agonist. We propose three aims to: 1.) SyntheSize 50 grams of compound 1 and evaluate its effect onTSH receptors in cells, 2.) Determine pharmacokinetics in rats, and 3.) Identify a safe dose of compound 1 for pre-IND investigations. Also, we will evaluate the genotoxicity of this compound in rats. The successful completion of this phase I SBIR willallow compound 1 to be advanced to a phase II application to develop a new diagnostic for use in patients with thyroid cancer.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government